Editas Medicine, Inc. EDIT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2016 · data as of November 13, 2026
Editas Medicine, Inc. (EDIT) is a healthcare company listed in the US with a market value of about $335M. In the twelve months to September 30, 2026 it had revenue of $50M and net income of -$72M, a net margin of -145.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -15% a year, a 5-year average ROIC of -63%.
About Editas Medicine
Editas Medicine is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2016. Revenue went from $6M in 2016 to $41M in 2025, growth of about 23.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 29% over three years (dilution for shareholders). It spends 222% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M |
| Net income | -$72M | -$160M | -$237M | -$153M | -$220M | -$193M | -$116M | -$134M | -$110M | -$120M | -$97M |
| Free cash flow | -$110M | -$166M | -$219M | -$137M | -$181M | -$172M | -$187M | -$47M | -$50M | -$11M | -$54M |
| EPS (diluted) | $-0.54 | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | $-2.33 | $-2.98 | $-3.02 |
| Net margin | -145.0% | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1605.5% |
| ROIC | — | -121.5% | -87.5% | -34.7% | -44.1% | -26.3% | -25.4% | -38.2% | -35.1% | -44.0% | -53.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $6.10, 181% above the current price; targets range from $1.00 to $15.00; the consensus rating is “Buy”; expected EPS is $-0.75 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Editas Medicine pay a dividend?
Not currently.
Is Editas Medicine a good stock to buy?
We do not give buy or sell advice. Editas Medicine scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.